Source:http://linkedlifedata.com/resource/pubmed/id/17609426
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2007-10-23
|
| pubmed:abstractText |
We performed fluorescent in situ hybridization (FISH) for 16q23 abnormalities in 861 patients with newly diagnosed multiple myeloma and identified deletion of 16q [del(16q)] in 19.5%. In 467 cases in which demographic and survival data were available, del(16q) was associated with a worse overall survival (OS). It was an independent prognostic marker and conferred additional adverse survival impact in cases with the known poor-risk cytogenetic factors t(4;14) and del(17p). Gene expression profiling and gene mapping using 500K single-nucleotide polymorphism (SNP) mapping arrays revealed loss of heterozygosity (LOH) involving 3 regions: the whole of 16q, a region centered on 16q12 (the location of CYLD), and a region centered on 16q23 (the location of the WW domain-containing oxidoreductase gene WWOX). CYLD is a negative regulator of the NF-kappaB pathway, and cases with low expression of CYLD were used to define a "low-CYLD signature." Cases with 16q LOH or t(14;16) had significantly reduced WWOX expression. WWOX, the site of the translocation breakpoint in t(14;16) cases, is a known tumor suppressor gene involved in apoptosis, and we were able to generate a "low-WWOX signature" defined by WWOX expression. These 2 genes and their corresponding pathways provide an important insight into the potential mechanisms by which 16q LOH confers poor prognosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ChiecchioLauraL,
pubmed-author:CrossNicholas C PNC,
pubmed-author:Dachs CabanasElisabetE,
pubmed-author:DagradaGian PaoloGP,
pubmed-author:DaviesFaith EFE,
pubmed-author:DickensNicholas JNJ,
pubmed-author:ElseMonicaM,
pubmed-author:GonzalezDavidD,
pubmed-author:JennerMatthew WMW,
pubmed-author:JohnsonDavid CDC,
pubmed-author:LeonePaola EPE,
pubmed-author:MorganGareth JGJ,
pubmed-author:NightingaleMathewM,
pubmed-author:ProtheroeRebecca K MRK,
pubmed-author:RossFiona MFM,
pubmed-author:StockleyDavidD,
pubmed-author:WalkerBrian ABA
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
110
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3291-300
|
| pubmed:meshHeading |
pubmed-meshheading:17609426-Adult,
pubmed-meshheading:17609426-Aged,
pubmed-meshheading:17609426-Aged, 80 and over,
pubmed-meshheading:17609426-Chromosome Mapping,
pubmed-meshheading:17609426-Chromosomes, Human, Pair 16,
pubmed-meshheading:17609426-Gene Expression Profiling,
pubmed-meshheading:17609426-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17609426-Humans,
pubmed-meshheading:17609426-Loss of Heterozygosity,
pubmed-meshheading:17609426-Middle Aged,
pubmed-meshheading:17609426-Multiple Myeloma,
pubmed-meshheading:17609426-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:17609426-Oxidoreductases,
pubmed-meshheading:17609426-Prognosis,
pubmed-meshheading:17609426-Survival Analysis,
pubmed-meshheading:17609426-Translocation, Genetic,
pubmed-meshheading:17609426-Tumor Cells, Cultured,
pubmed-meshheading:17609426-Tumor Suppressor Proteins
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
|
| pubmed:affiliation |
Section of Haemato-Oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|